The US Food and Drug Administration (FDA) has accepted Bristol Myers Squibb’s (BMS) supplemental biologics licence ...

David Zhen, MD, discussed the relevance of nivolumab in the upper gastrointestinal cancer population. In an interview with ...

More than a decade after Merck’s Keytruda and BMS’ Yervoy ushered in the immuno-oncology revolution, the space is at a ...

The FDA accepted a supplemental biologics license application for Opdivo plus Yervoy as a first-line treatment for some adult ...

Navy veteran Kyle Lewis was diagnosed with Stage 4 cancer in 2020. Now he says his cancer treatment is at risk due to federal research cuts.

The FDA has started a priority review of Bristol Myers Squibb's Opdivo and Yervoy as a first-line therapy for patients with a ...

Bristol Myers' Opdivo plus Yervoy gets FDA Priority Review for first-line MSI-H/dMMR metastatic colorectal cancer, with a ...

Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental biologics ...

Genitourinary Cancer Symposium 2025, held on 13-15 February, final results from the randomised, multicentre, double-blind, ...

Squibb announced that the U.S. FDA has accepted the supplemental biologics license application for Opdivo plus Yervoy as a ...